Behboudi Farahbakhsh Faegheh, Nazemalhosseini Mojarad Ehsan, Azimzadeh Pedram, Goudarzi Faezeh, Mohammad Alizadeh Amir Houshang, Haghazali Mehrdad, Mahmoudi Lamoki Reza, Asadzadeh Aghdaei Hamid
Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center,Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gastroenterology and Liver Diseases Research Center,Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gastroenterol Hepatol Bed Bench. 2017 Winter;10(1):14-20.
Ninety percent of pancreatic cancer patients have less than 5-year overall survival and approximately 50% of cases were diagnosed with metastasis in the time of admission. Previous evidences have demonstrated the strong association between TGF-β1 variations and cancer susceptibility so far.
A total of 78 patients with pancreatic cancer and 94 healthy controls were enrolled in this case- control study between 2007 and 2012. Genomic DNA was isolated from peripheral blood samples according to phenol chloroform extraction. The genotypes of TGF-β1 rs rs1800469 and rs1800471 were determined using the polymerase chain reaction-restriction fragment length polymorphism method.
The mean age of cases and the control group were 64.50 ± 13.718 and 40.12 ± 16.001, respectively. For polymorphism -509 C>T, the frequency of TT genotype were 31 (33.0), CT, 47(50) and CC, 16 (17) in control and 19 (24.4), 45 (57.7) and 14 (17.9) in cases respectively. In position +915 G>C, the frequency of GG genotype was 84 (89.4) and GC, 10 (10.6) in control and 71 (91.0) and 7 (9) in cases, respectively. We did not observe any significant differences in the genotype and allele frequencies of the TGF-β1-509 C>T (rs1800469) and codon +915 G>C (rs1800471) between the two study groups (P>0.05).
we found that TGF-β1 gene polymorphisms rs1800469 and rs1800471 might not play a role in pancreatic cancer susceptibility in Iranian population.
90%的胰腺癌患者总生存期不足5年,约50%的病例在入院时被诊断为已有转移。目前已有证据表明,转化生长因子-β1(TGF-β1)变异与癌症易感性之间存在密切关联。
2007年至2012年期间,本病例对照研究共纳入78例胰腺癌患者和94例健康对照。根据酚氯仿提取法从外周血样本中分离基因组DNA。采用聚合酶链反应-限制性片段长度多态性方法测定TGF-β1 rs1800469和rs1800471的基因型。
病例组和对照组的平均年龄分别为64.50±13.718岁和40.12±16.001岁。对于-509 C>T多态性,对照组中TT基因型的频率为31(33.0%),CT为47(50%),CC为16(17%);病例组中分别为19(24.4%)、45(57.7%)和14(17.9%)。在+915 G>C位点,对照组中GG基因型的频率为84(89.4%),GC为10(10.6%);病例组中分别为71(91.0%)和7(9%)。我们未观察到两个研究组之间TGF-β1 -509 C>T(rs1800469)和密码子+915 G>C(rs1800471)的基因型和等位基因频率存在任何显著差异(P>0.05)。
我们发现TGF-β1基因多态性rs1800469和rs1800471可能在伊朗人群的胰腺癌易感性中不起作用。